AKEBIA THERAPEUTICS, INC. Increase (Decrease) in Other Noncurrent Liabilities
AKEBIA THERAPEUTICS, INC. (AKBA) reported Increase (Decrease) in Other Noncurrent Liabilities of -$474.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2026-06-30 was -$119.00K, a 149.58% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2026-03-31 was -$355.00K, a 197.26% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-12-31 was -$365.00K, a 238.26% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-09-30 was -$352.00K.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in other noncurrent liabilities for fiscal 2025 was -$112.00K.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in other noncurrent liabilities for fiscal 2024 was -$6.20M.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in other noncurrent liabilities for fiscal 2023 was -$5.69M, a 349.93% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in other noncurrent liabilities for fiscal 2022 was $2.28M.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 3 month as first filed | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 6 month as first filed | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$119.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$474.00K 10-Q · filed 2026-08-05 | -$839.00K derived: sum of 3 quarters · filed 2026-08-05 | -$1.19M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | -$355.00K 10-Q · filed 2026-05-07 | -$720.00K derived: sum of 2 quarters · filed 2026-05-07 | -$1.07M derived: sum of 3 quarters · filed 2026-05-07 | -$832.00K derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | -$365.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$717.00K derived: sum of 2 quarters · filed 2026-02-26 | -$477.00K derived: sum of 3 quarters · filed 2026-08-05 | -$112.00K 10-K · filed 2026-02-26 | |||
| 2025-09-30 | -$352.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$112.00K derived: sum of 2 quarters · filed 2026-08-05 | $253.00K 10-Q · filed 2025-11-10 | $517.00K derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $240.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $605.00K 10-Q · filed 2026-08-05 | $869.00K derived: sum of 3 quarters · filed 2026-08-05 | -$2.12M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $365.00K 10-Q · filed 2026-05-07 | $629.00K derived: sum of 2 quarters · filed 2026-05-07 | -$2.36M derived: sum of 3 quarters · filed 2026-05-07 | -$4.24M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $264.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.73M derived: sum of 2 quarters · filed 2026-02-26 | -$4.60M derived: sum of 3 quarters · filed 2026-02-26 | -$6.20M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | -$2.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$4.87M derived: sum of 2 quarters · filed 2025-11-10 | -$6.47M 10-Q · filed 2025-11-10 | -$4.93M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-06-30 | -$1.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$3.48M 10-Q · filed 2025-08-07 | -$1.94M derived: sum of 3 quarters · filed 2026-02-26 | -$9.65M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | -$1.60M 10-Q · filed 2025-05-08 | -$64.00K derived: sum of 2 quarters · filed 2026-02-26 | -$7.77M derived: sum of 3 quarters · filed 2026-02-26 | -$7.86M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$6.17M derived: sum of 2 quarters · filed 2026-02-26 | -$6.26M derived: sum of 3 quarters · filed 2026-02-26 | -$5.69M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | -$7.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$7.80M derived: sum of 2 quarters · filed 2024-11-07 | -$7.23M 10-Q · filed 2024-11-07 | $9.87M derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2023-06-30 | -$92.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $481.00K 10-Q · filed 2024-08-08 | $17.58M derived: sum of 3 quarters · filed 2024-08-08 | $11.38M derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | $573.00K 10-Q · filed 2024-05-09 | $0.00 10-Q · filed 2023-05-08 | $17.67M derived: sum of 2 quarters · filed 2024-05-09 | $11.47M derived: sum of 3 quarters · filed 2024-05-09 | $6.04M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $17.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $10.90M derived: sum of 2 quarters · filed 2024-03-14 | $5.47M derived: sum of 3 quarters · filed 2024-03-14 | $2.28M 10-K · filed 2024-03-14 | $2.08M 10-K · filed 2023-03-10 | ||
| 2022-09-30 | -$6.20M derived: 10-Q 9 month − 10-K/A 6 month · filed 2023-11-08 | -$11.63M derived: sum of 2 quarters · filed 2023-11-08 | -$14.82M 10-Q · filed 2023-11-08 | -$27.99M derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | -$5.43M derived: 10-K/A 6 month − 10-K/A 3 month · filed 2023-08-28 | -$8.62M 10-K/A · filed 2023-08-28 | -$9.03M 10-Q · filed 2022-08-04 | -$21.79M derived: sum of 3 quarters · filed 2023-08-28 | -$21.79M derived: sum of 4 quarters · filed 2023-08-28 | ||
| 2022-03-31 | -$3.19M 10-K/A · filed 2023-08-28 | -$16.36M derived: sum of 2 quarters · filed 2023-08-28 | -$16.36M derived: sum of 3 quarters · filed 2023-08-28 | -$16.36M derived: sum of 4 quarters · filed 2023-08-28 | |||
| 2021-12-31 | -$13.17M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | -$13.17M derived: sum of 2 quarters · filed 2023-08-28 | -$13.17M derived: sum of 3 quarters · filed 2023-08-28 | -$13.17M 10-K/A · filed 2023-08-28 | -$12.48M 10-K · filed 2022-03-01 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | |||||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-09 | ||||||
| 2020-12-31 | $1.25M 10-K/A · filed 2023-08-28 | $0.00 10-K · filed 2022-03-01 | |||||
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |